Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Livzon Pharmaceutical Group Inc updates on cross listing


Monday, 16 Dec 2013 07:00pm EST 

Livzon Pharmaceutical Group Inc:Says the company's stock will stop trading since Dec. 23.Says the cash option exercise subscription period is from Dec. 26, 2013 to Jan. 2, 2014.Says after the mentioned period, under the condition that the top three public shareholders' stake exceeds a 50 pct of total holdings held by public shareholders of its B stock, the company's cross listing on Stock Exchange of Hong kong will be terminated. 

Company Quote